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Abstract
Previous studies have shown that key enzymes involved in lipid metabolic pathways are differentially expressed in
normal compared with tumor tissues. However, the precise role played by dysregulated expression of lipid metabolic
enzymes and altered lipid homeostasis in carcinogenesis remains to be established. Fatty acid synthase is over-
expressed in a variety of cancers, including breast and prostate. The purpose of the present study was to examine
the expression patterns of additional lipid metabolic enzymes in human breast and prostate cancers. This was ac-
complished by analysis of published expression databases, with confirmation by immunoblot assays. Our results
indicate that the fatty acid–activating enzyme, long-chain fatty acyl-CoA synthetase 4 (ACSL4), is differentially ex-
pressed in human breast cancer as a function of estrogen receptor alpha (ER) status. In 10 separate studies, ACSL4
messenger RNA (mRNA) was overexpressed in ER-negative breast tumors. Of 50 breast cancer cell lines examined,
17 (89%) of 19 ER-positive lines were negative for ACSL4 mRNA expression and 20 (65%) of 31 ER-negative lines
expressed ACSL4 mRNA. The inverse relationship between ER expression and ACSL4 expression was also observed
for androgen receptor status in both breast and prostate cancers. Furthermore, loss of steroid hormone sensitivity,
such as that observed in Raf1-transfected MCF-7 cells and LNCaP-AI cells, was associated with induction of ACSL4
expression. Ablation of ACSL4 expression inMDA-MB-231 breast cancer cells had no effect on cell proliferation; how-
ever, sensitivity to the cytotoxic effects of triacsin C was increased three-fold in the cells lacking ACSL4.
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Introduction
A role for altered lipid metabolism in the genesis of the malignant
phenotype is suggested by the increased expression of the fatty acid bio-
synthetic enzymes fatty acid synthase (FASN) and acetyl Co-A carbox-
ylase (ACC) in a variety of tumors, including those that develop in
breast and prostate tissues [1,2]. Whereas FASN and ACC are re-
sponsible for de novo synthesis of free fatty acids, use of these lipids
in subsequent metabolic events, such as glycerolipid synthesis and
β-oxidation, requires activation through condensation with a molecule
of CoA. There is evidence that activated fatty acids, themselves, can
function as transcription factors [3]. The enzymes responsible for the
activation reaction comprise a family of proteins known as fatty acyl-
CoA synthetases that are classified according to the chain length of their
preferred substrates (short, medium, long, and very long). There are
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five different mammalian isoforms of the long-chain family (ACSL1,
3, 4, 5, and 6), which differ in subcellular localization and substrate
specificity [4]. It has been suggested that individual isoforms may serve
to channel fatty acids to specific metabolic pathways. ACSL4, for ex-
ample, is localized to both peroxisomes andmitochondria as a peripheral,
rather than integral, membrane protein and has a marked preference for
arachidonic and eicosapentaenoic acid as substrates. ACSL4 messenger
RNA (mRNA) is highly expressed in placenta, brain, testis, ovary,
spleen, and adrenal gland. Relatively low expression levels have been
reported in the gastrointestinal tract, including liver, colon, and small
intestine [5]. Interestingly, ACSL4 is overexpressed in colon and liver
cancer specimens [6,7].Here, we report that this enzyme is overexpressed
in estrogen receptor (ER)–negative, androgen receptor (AR)–negative
breast tumors and cell lines, and in AR-negative prostate tumors and
cell lines. In addition, our studies suggest that expression of ACSL4 is
indicative of steroid hormone-independent growth.
Materials and Methods
Cell Lines and Cell Culture
MCF-7, MDA-MB-231, and MDA-MB-415 cells were obtained
from American Type Culture Collection (Manassas, VA). T47D cells
were a gift fromDavid Kleinberg of this institution; SKBR3 and BT-20
cells were a gift fromHerbert Samuels of this institution; and DU145,
PC3, LNCaP, and LNCaP-AI cells were previously described [8,9].
Cells were routinely grown at 37°C in a humidified atmosphere
in Dulbecco’s minimal essential medium (high-glucose) containing
Earle’s salts and supplemented with 10% fetal bovine serum and anti-
biotics (penicillin [100 U/ml], Fungizone [0.25 μg/ml], and strepto-
mycin [100 μg/ml]). All cell culture reagents were from Invitrogen
(Carlsbad, CA).
Analysis of ACSL4 Protein Expression
Cells were grown in either 96-well or 24-well plates. After a wash
with phosphate-buffered saline without calcium or magnesium, either
40 μl (96-well) or 200 μl (24-well) of sample buffer (10 mM Tris-
HCl, 1 mM EDTA, 2.5% SDS, 5% β-mercaptoethanol, 0.01%
bromophenol blue, pH 8.0) was added to the well. Samples were then
heated to 95°C for 5 minutes. Electrophoresis was performed using the
PhastGel System from GE Healthcare (Piscataway, NJ). Precast 7.5%
acrylamide gels were used with SDS buffer strips. We subjected either 1
or 4 μl of individual samples to electrophoresis. We used Precision Plus
protein standards from Bio-Rad (Hercules, CA) as molecular weight
markers. After separation, the proteins were transferred to a polyvinylidene
fluoridemembrane (Hydrabond-P) using the PhastGel transfer apparatus.
The membrane was then blocked with 5% milk in phosphate-buffered
saline–Tween (0.1%) for 1 hour, followed by an overnight incubationwith
a 1:2000 dilution of affinity purified rabbit anti-ACSL4 antibody [6]. A
1:5000 dilution of goat antirabbit HRP secondary antibody was used for
the final step. Signals were visualized using ECL-Plus chemiluminescence
reagent. All immunoblot reagents were from GE Healthcare, with the
exception of the antibody to β-actin, which was purchased from Cell Sig-
naling Technologies (Danvers, MA). Quantitation of band densities was
accomplished using the Quantity One program from Bio-Rad.
Quantitation of Relative Cell Number
Relative differences in cell number were quantitated using the Cell
Titer 96 AQueous Reagent purchased from Promega (Madison, WI).
Protocols used were as described by the manufacturer.
Small Interfering RNA–Mediated Knockdown of ACSL4
Cells were plated in T-25 flasks in complete medium lacking anti-
biotic and allowed to attach overnight. Cell densities at the start of the
experiment were between 30% and 60%. Transfection of small in-
terfering RNA (siRNA; either control or ACSL4-specific Smart Pool
siRNA purchased from Dharmacon, Lafayette, CO) into cells was ac-
complished using Lipofectamine RNAiMAX (Invitrogen) according to
the protocol recommended by the manufacturer. Transfections were
carried out for 48 hours.
Bioinformatics
Expression data derived fromAffymetrix arrays were obtained from the
following public databases: Oncomine (http://www.oncomine.org/),
Array Express (http://www.ebi.ac.uk/), and Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/). The data shown represent the base
2 logarithms of the original values.
Statistical Analyses
A Student’s t test (two-tailed) was used to determine significance,
unless otherwise noted.
Results
Expression of ACSL4 in Breast Tumor Samples and Cell Lines
A search of the Oncomine database [10] yielded 10 separate studies
that reported overexpression of ACSL4 mRNA in human ER-negative
breast tumor samples [11–20]. Figure 1A illustrates the results of these
studies. For the study by Miller et al. [11], we analyzed the relationship
between ER and ACSL4mRNA expression levels. Figure 1B shows that
there is a highly significant inverse correlation between expression levels
of ER and ACSL4 mRNA (P < .0001). ACSL1, 5, and 6 were also
overexpressed in ER-negative tumor samples, but associated P values
were generally 10-fold higher. ACSL3 expression, however, was down-
regulated in ER-negative tumors compared with ER-positive tumors in
four separate studies [14,18,21,22] with P < .001.
To further investigate the relationship between ACSL4 mRNA levels
and ER status, we analyzed microarray expression data reported for
50 human breast cancer cell lines [23]. Figure 2A illustrates results for
expression of the five ACSL isoforms in these cell lines as a function of
ER status. We found that ACSL4 mRNA expression was significantly
higher in ER-negative cells (P < .0001), whereas expression of ACSL3
mRNA was significantly lower (P = .015). We detected no differences
in expression of ACSL1, 5, or 6 as a function of ER status. Figure 2B
illustrates the range of ACSL4 mRNA expression levels seen in the vari-
ous cell lines.
Our next goal was to evaluate whether the observed differences in
ACSL4 mRNA expression were recapitulated at the protein level, and
whether these putative differences were an exclusive property of ASCL4.
To accomplish this, we assessed the levels of ACSL1 and ACSL4 protein
relative to those of β-actin, using immunoblot analyses of protein ex-
tracts isolated from ER-positive and ER-negative breast cancer cell lines
(Figure 2C).We found that all the cell lines expressed detectable levels of
ACSL1. These results were consistent with microarray studies that dem-
onstrated expression of ACSL1mRNA in these cell lines (Figure 2A). In
addition, we found no correlation between ER status and ACSL1 pro-
tein expression levels (Figure 2C), a finding consistent with studies at
the mRNA level (Figure 2A). However, with respect to ACSL4, only
those cells with normalized mRNA expression values greater than 2.9
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appeared positive for ACSL4 by immunoblot analysis (Figure 2C ).
BT-20 cells had an intensity value of 4.55; MCF-7 cells, 2.52; MDA-
MB-231 cells, 5.20; MDA-MB-415 cells, 3.14; SKBR3 cells, 2.77; and
T47D cells, 2.62. Using the cutoff for expression indicated by the re-
sults from the immunoblot analyses, 17 (89%) of 19 ER-positive cell
lines were negative for ACSL4 and 20 (65%) of 31 of ER-negative cells
were positive for ACSL4 expression.
AR Status and ACSL4 Expression
A subset of mammary tumors known as molecular apocrine is
ER-negative, AR-positive. Analysis of microarray expression data in
this subset of breast cancers and in basal (ER-negative, AR-negative)
and luminal (ER-positive, AR-positive) breast tumors [24] revealed
that ACSL4 mRNA levels were significantly lower in the molecular
apocrine samples compared with the basal subset (P < .001, data not
shown). Interestingly, of the 11 ER-negative cell lines that do not
express ACSL4, 3 showed high levels of expression of AR mRNA.
One of these cell lines, MDA-MB-453, has been shown to have a
positive proliferative response to androgens [25]. To assess whether ex-
pression of ACSL4 and AR were inversely related, we first evaluated
results from microarray studies in an ER-negative subset of tumors
[14]. Interestingly, we found a significant inverse correlation between
AR and ACSL4 mRNA expression levels (Figure 3A) reminiscent of
that observed between ER and ACSL4. To explore this issue further,
Figure 2. Effect of ER status on expression of ACSL4 in human
breast cancer cell lines. Data provided by Array Express represents
the log to the base 2 of the original data. (A) Expression levels of
ACSL mRNA in human breast cancer cells. The expression data
for 19 ER-positive (open bars) and 31 ER-negative (solid bars) breast
cancer cell lines was compared for the five known isoforms of mam-
malian ACSL (1, 3, 4, 5, and 6). Values shown are the mean ± SD.
(B) Individual ACSL4 mRNA expression values for each cell line. The
horizontal line indicates the cutoff, as determined by immunoblot,
of ACSL4 positivity. (C) ACSL4 and ACSL1 protein expression in
selected breast cancer cell lines. Immunoblot analyses were per-
formed as described in Materials and Methods.
Figure 1. Expression of ACSL4 mRNA in human breast tumor sam-
ples. (A) Comparison of ASCL4 mRNA levels in ER-negative (solid
bars) versus ER-positive human (open bars) breast tumors in ten in-
dependent gene expression profile data sets (denoted by study first
author). Box-and-whisker plots indicate median, lower, and upper
quartiles, and the smallest and largest values. Differences between
ER-positive and ER-negative values are significant with P < .001 for
all studies represented. Data provided by Oncomine as normalized
expression units. (B) Relationship between ACSL4 expression and
ESR1 (ER) expression in the study by Miller et al. [11]. The samples
evaluated comprised 34 ER-negative and 213 ER-positive tumors.
Data provided by Oncomine as normalized expression units.
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we compared AR and ACSL4 expression levels in prostate cancer cells.
First, we analyzed data from a study that assessed mRNA expression in
prostate cancer cell lines [26] and found that ACSL4 mRNA was over-
expressed in AR-negative cell lines (data not shown). Second, to estab-
lish whether the differences in mRNA expression were recapitulated at
the protein level, we assessed ACSL4 and β-actin expression in extracts
from two AR-negative cell lines (PC3 and DU145), one AR-positive
cell line (LNCaP), and one AR-positive cell line that is androgen-
independent for growth (LNCaP-AI [9]). Figure 3B illustrates the re-
sults. We found that both of the AR-negative lines expressed high levels
of ACSL4, whereas the AR-positive line did not express the protein.
Importantly, we observed that loss of androgen sensitivity in LNCaP-
AI cells was associated with increased expression of ACSL4, even in the
presence of AR (Figure 3B). Finally, we analyzed results from an mRNA
expression study in human prostate tumors [27] and found that ACSL4
levels were inversely correlated with AR expression (Figure 3C). These
combined data strongly suggest negative links between steroid hormone
receptor andACSL4 expression that could reflect functional relationships
in growth requirements or signaling events involving these proteins.
ACSL4 Expression in MCF-7 Cells Engineered to Overexpress
Members of the Mitogen-Activated Protein Kinase (MAPK)
Signaling Pathway
Our next goal was to start to identify intermediates that linked ste-
roid hormone receptor and ACSL4 expression. Creighton et al. [28]
previously reported that overexpression of key members of the mitogen-
activated protein kinase (MAPK) signaling pathway inMCF-7 cells results
in a molecular fingerprint characteristic of ER-negative human breast tu-
mors. Our studies showed that MCF-7 cells, which express ER and are
estrogen-dependent with respect to growth, express ACSL1 but do not ex-
press ACSL4 (Figure 2C). We hypothesized that genetic manipulation of
MCF-7 cells leading to the expression of the ER-negative phenotype may
also result in altered ACSL4 expression. To test this, we analyzed public
microarray expression data sets from MCF-7 cells genetically manipu-
lated to activate signaling through MAPK (Figure 4). We focused our
attention on the expression of two genes, ESR1 (probe 205225_at) and
ACSL4 (probe 202422_s_at), and found that transfection with constitu-
tively active Raf-1 caused induction of ACSL4 (P = .0009; Figure 4).
Overexpression of Raf-1 was also accompanied by loss of expression
of ER mRNA (P < .0001), a finding consistent with a previous study
showing loss of ER protein after transfection of MCF-7 cells with
Raf-1 [29]. Interestingly, ACSL3 expression was downregulated in
Raf-1–overexpressing cells (data nor shown).
Effect of ACSL4 Ablation on MDA-MB-231 Cells
Because the evidence suggested that ACSL4 expression was associ-
ated with sex steroid hormone–independent growth, we wondered if
ablation of this enzymatic activity would impact the ability of cells to
proliferate. Clearly, the activity was not required for proliferation,
in general, as evidenced by the ability of cells lacking ACSL4, such as
MCF-7 and T47D, to grow quite well without it. A greater-than 95%
reduction in ACSL4 protein expression was achieved by treating cells
for 48 hours with ACSL4-specific siRNA, as shown in Figure 5A. The
knockdown effect persisted for at least 3 days after removal of the trans-
fection medium (data not shown). When proliferation of the knock-
down cells was compared with that of control cells, no difference was
observed (Figure 5B).
Figure 3. Effect of AR status on expression of ACSL4. (A) Relation-
ship between AR and ACSL4 mRNA expression in 77 ER-negative
breast tumor samples as reported in a study byWang et al. [14]. Data
provided by Oncomine. (B) Expression of ACSL4 protein in pros-
tate cancer cell lines. Immunoblot analyses were performed as de-
scribed in Materials and Methods. (C) Relationship between AR and
ACSL4 mRNA levels in 98 human prostate tumors as reported by
Holzbeierlein et al. [27]. Data provided by Gene Expression Omnibus.
Figure 4. Induction of ACSL4 expression in MCF-7 cells constitu-
tively expressing Raf-1. Data provided by Gene Expression Omni-
bus. C indicates control; EI, long-term E2-independent growth;
erbB-2, cells overexpressing constitutively active c-erbB-2; MEK,
cells overexpressing constitutively active MEK; Raf-1, cells over-
expressing constitutively active Raf-1; EGFR, cells overexpressing
ligand-activatable EGFR. Results shown are derived from the means
of three separate determinations.
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The ACSL inhibitor, triacsin C, is specific for inhibition of ACSL1,
3, and 4, with little or no effect on the activities of ACSL5 or 6 [30].
The half-maximal inhibitory concentration values reported for the three
sensitive isoforms indicate that ACSL1 is the most sensitive, whereas
ACSL4 is the least sensitive. In addition, this reagent has been demon-
strated to inhibit proliferation and induce apoptosis in a variety of can-
cer cells [31]. When we compared the effect of triacsin C treatment on
MDA-MB-231 control and knockdown cells, the results shown in
Figure 5C were obtained. Ablation of cellular ACSL4 resulted in a
three-fold increase in triacsin C sensitivity. The half-maximal inhibitory
concentration for triacsin C was 1.59 μM for control cells and 0.56 μM
for ACSL4 knockdown cells. These data suggest that ACSL4 activity
makes a significant contribution to the overall ACSL activity required
for growth and survival of cells.
Prognostic Implication of ACSL4 Expression in
ER-Negative Tumors
Because the expression of ACSL4 mRNA in ER-negative tumors
varies from strong to none, we next investigated whether ACSL4 levels
might have potential prognostic value. Using expression data from a
study byWang et al. [14], we correlated the level of expression of ACSL4
(high or low with respect to the median as cut point) with time of dis-
tant metastasis-free survival in 77 node-negative patients who did not
receive systematic adjuvant therapy. The results of this analysis are
shown in Figure 6. There was a significant difference between the groups
(P < .05), suggesting that expression of ACSL4may have prognostic value.
Discussion
Altered expression of lipid metabolic enzymes is a feature of a variety of
cancers, including those that develop in breast tissues [32–34]. Both
FASN and ACC have been shown to be essential for breast cancer cell
survival [35], and inhibition of FASN activity has been shown to have
potential chemopreventive [36] and therapeutic [37,38] applications.
However, the precise role of altered lipid metabolism in the expression
of the malignant phenotype has not been extensively studied. The
reported increase in FASN activity in cancer cells may reflect high re-
quirements of these proliferating cells for fatty acids; however, it is
unclear whether these fatty acids are necessary for glycerolipid bio-
synthesis, used as an alternative energy source, or both. It has been re-
ported that prostate cancer cells rely on fatty acids as an energy source
[39], and several studies have found that blockade of FASN activity
inhibits the growth of cancer cells [37]. A relationship between FASN
expression and growth regulatory pathways has also been demon-
strated [40].
The first step in the use of free fatty acids for either glycerolipid
synthesis or β-oxidation is condensation with a molecule of CoA, a
Figure 5. Effect of ablation of ACSL4 expression on proliferation of
MDA-MB-231 cells. Cells were treated for 48 hours with either a con-
trol or ACSL4-specific siRNA as described in the text. Cells were
then harvested and replated in multiwell plastic dishes and treated
as described. (A) Immunoblot of cellular protein after a 48-hour trans-
fection with no addition (−), control siRNA (C), or ACSL4–siRNA (A).
Methodswere as described in the text. (B) Growth curve of cells after
48 hours of treatment with control or ACSL4–siRNA. (C) Effects of
triacsin C on relative cell number after 48 hours of treatment with
control or ACSL4–siRNA. Relative cell numbers were assayed as de-
scribed in the text. Values shown are means ± SD.
Figure 6. Correlation of ACSL4 mRNA levels with time to distant
metastasis in ER-negative tumors. Kaplan-Meier analysis of 77 ER-
negative tumors from node-negative patients who did not receive
systematic adjuvant therapy. The log-rank test evaluates whether
there are significant differences between tumors harboring high
versus low ACSL4 levels. The univariate Cox test evaluates the as-
sociation of ACSL4 with patient outcome, when the expression val-
ues are treated as a continuous variable (i.e., without making a cut).
Data provided by Oncomine from a study by Wang et al. [14].
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reaction that is catalyzed by ACSLs. Thus far, five mammalian ACSLs
that differ in subcellular location and substrate specificity have been
identified [4]. The precise role of each isoform has not been delineated,
but current evidence suggests that ACSL1 functions in hepatic glycero-
lipid synthesis [41,42], whereas ACSL3 and ACSL5 seem to increase
β-oxidation of fatty acids in certain cells [43]. The localization of
ACSL4 to peroxisomes suggests that this enzyme may function in fatty
acid oxidation [44]. Inhibitor studies indicate that ACSL4 may also
be involved in hepatic triacylglycerol synthesis [45]. Deletion of the
human ACSL4 gene has been associated with Alport syndrome, ellipto-
cytosis, and mental retardation [46], and a mutated form of ACSL4 has
been reported to be associated with X-linked mental retardation [47].
Mice heterozygous for ACSL4 deficiency present with abnormal uteri
[48]. These studies indicate essential roles for ACSL4 in normal devel-
opment and in reproduction.
It was previously shown that ACSL4 is overexpressed in colon and
liver cancers [6,49,50], but to our knowledge, no studies in breast cancer
have been reported to date. Comprehensive analyses of public expres-
sion databases indicated that ACSL4 mRNA expression is elevated in
a subset of human breast cancer specimens. In addition, the data show
that overexpression of ACSL4 occurs mainly in ER-negative tumors.
We made similar observations in human breast cancer cell lines. Indeed,
our analyses showed that 17 (89%) of 19 ER-positive cell lines were
negative for ACSL4 expression, whereas 20 (65%) of 31 ER-negative
lines expressed ACSL4 to varying degrees. Because a previous report
indicated that changes in ACSL4 mRNA levels do not always reflect
alterations in protein levels [51], we analyzed several breast cancer cell
lines for ACSL4 protein expression. Our studies showed robust correla-
tion between ACSL4mRNA and protein expression, and they validated
use of mRNA expression data sets as good indicators of ACSL4 protein
expression. Our combined studies strongly suggested that ER status and
ACSL4 protein levels were inversely correlated in human breast cancer.
The observation that several of the ER-negative, ACSL4-negative
breast cells lines were positive for expression of ARmRNA led us to pos-
tulate that ACSL4 expression may also be linked to that of AR. The
microarray data available for prostate tumor samples confirmed a nega-
tive correlation between ACSL4 expression and AR expression. To fur-
ther examine this relationship, we analyzed ACSL4 expression in a
variety of human prostate cancer cell lines and found that cells express-
ing AR lacked ACSL4, whereas those lacking AR expressed ACSL4.
Interestingly, AR-positive prostate cancer cells that have developed the
ability to grow in an androgen-independent fashion (LNCaP-AI) [52]
now express ACSL4. Expression of ACSL3, conversely, has been reported
to be stimulated by androgen treatment in prostate cancer [53]. Thus,
we concluded that expression of ACSL4 was indicative of androgen in-
sensitivity rather than simply absence of AR.
To further examine the relationship between hormone dependence
and ACSL4 expression, we analyzed the consequences of loss of estro-
gen dependence inMCF-7 breast cancer cells. ER-positive MCF-7 cells
in which theMAPK growth pathway is constitutively activated by over-
expression of Raf-1 [28] have been shown to lose ER expression and
exhibit an ER-negative molecular fingerprint. An examination of the
microarray data accompanying these experiments indicates that Raf-1
overexpression and loss of ER are accompanied by induction of ACSL4
expression in these MCF-7 cells. Interestingly, constitutive activation
of the MAPK pathway through overexpression of other elements of
the pathway, such as EGFR or erbB2, did not result in induction of
ACSL4 expression. It is important to emphasize that these correlative
studies do not necessarily reflect causal functional relationships. How-
ever, an attractive possibility is that up-regulation of ACSL4 expres-
sion is necessary for hormone-independent growth of breast and/or
prostate tumors. Studies along these lines could have important trans-
lational implications.
Another contribution of this study is related to our observations sug-
gesting that ACSL4 levels may also have prognostic value. Approximately
10% of ER-positive tumors are unresponsive to hormone therapy, and
many attempts have been made to identify a marker of ER sensitivity
that complements ER expression data [54]. In general, expression of
ER-inducible proteins has been considered a good index of estrogen
sensitivity; however, this parameter may not always reflect hormone-
dependent cellular growth. It is possible that simultaneous expression
of both ER and ACSL4 might predict a lack of response to hormonal
therapy, and we are currently undertaking further studies to evaluate
this hypothesis.
With respect to ER-negative breast tumors, we found statistically sig-
nificant differences in the time of distant metastasis-free survival in
patient groups segregated based on ACSL4 mRNA expression levels.
It is likely that these differences will become even more significant if
protein levels are measured so that additional stratification can be made
based on positive or negative protein expression status. Additional stud-
ies will be required to assess the utility of ACSL4 levels as prognostic
biomarkers of breast cancer.
With respect to prostate cancer, it seems clear that the expression of
ACSL4 is correlated with hormone-independent growth; however, the
majority of prostate cancers are AR-positive, and it has been suggested
that failure of a prostate tumor to respond to hormone-ablative ther-
apy is most likely the result of increased sensitivity to androgens, rather
than loss of sensitivity [55]. Thus, ACSL4 expression data would be of
limited use.
The contribution of ACSL4 activity to the sex steroid receptor–
negative phenotype of human breast cancer remains to be determined.
There is evidence suggesting that ACSL3 plays a role in the response of
prostate cancer to androgens [26,56], and that ACSL5 promotes glioma
cell survival under extracellular acidosis conditions [57]. The induc-
tion of ACSL4 expression in sex steroid hormone–independent breast
cancer cells suggests that this activity plays a role in facilitating hormone-
independent growth, but the precise nature of this contribution remains
to be determined. Results of knockdown studies presented here indi-
cate that ACSL4 activity does not influence the growth or survival of
MDA-MB-231 cells under the conditions used. It is possible that ACSL4
activity provides an advantage to cancer cells grown under more strin-
gent conditions, such as low pH or hypoxia. But that ACSL4 activity
plays a role in the lipid metabolism of MDA-MB-231 cells is indicated
by the increased sensitivity of the cells to triacsin C after ablation of
ACSL4 expression.
In summary, we have presented data that confirm an association be-
tween sex steroid hormone expression and ACSL4 expression in human
breast and prostate cancer. More specifically, there is some evidence that
ACSL4 expression is more closely associated with hormone-independent
growth and, as such, may be a useful marker in determining response
to hormonal therapy; however, much more work will be needed to vali-
date such a conclusion.
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